Skip to content

The Effect of Intermittent Fasting on Body Composition in Women With Breast Cancer

EFFECT-BC: The EFFECT of Intermittent Fasting on Body Composition in Women With Breast Cancer

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04691999
Acronym
EFFECT-BC
Enrollment
0
Registered
2020-12-31
Start date
2021-12-02
Completion date
2023-08-31
Last updated
2021-11-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

intermittent fasting

Brief summary

The objective of this study is to evaluate intermittent fasting after the treatment of breast cancer with surgery and radiation therapy. All participants will either delay their first meal of the day or advance their last meal to achieve an approximate 16-18 hour fasting period four times per week. Over six months, the innovative protocol will 1) assess adherence, and is expected to 2) improve body composition, quality of life and inflammatory and metabolic variables linked with outcomes after breast cancer treatment. The long-term goal of this project is to incorporate this dietary strategy as a standard component of care for breast cancer patients.

Interventions

BEHAVIORALIntermittent Fasting

16-18 hour fasting period four times per week

Sponsors

Duke University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* biopsy proven diagnosis of ductal carcinoma in situ or invasive carcinoma of the breast stage I-III * completed any chemotherapy prior to initiation of the trial (adjuvant endocrine therapy is permitted) * BMI \> 25 kg/m2 or body fat% greater or equal to 31% * have a schedule amenable to nutrition and dietitian counseling described within the study protocol as determined by the treating radiation oncologist * have access to the internet and email with capability to join Zoom calls

Exclusion criteria

* Metastatic breast cancer * Currently receiving chemotherapy * Uncontrolled hypertension or diabetes, defined as systolic blood pressure over 149, diastolic blood pressure over 99, or hemoglobin A1c greater than 8.9. * Diabetic condition requiring the usage of insulin

Design outcomes

Primary

MeasureTime frameDescription
Adherence to the intermittent fasting program6 monthsas determined by the proportion of fasting days met divided by the total fasting days planned for each participant
Change in body fatbaseline, 6 monthsas measured by mean change in percent body fat between baseline and 6 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026